XL092 and Cemiplimab in BRAF WT Thyroid Cancer

This study is testing a combination of XL092 (a targeted therapy) and cemiplimab (an immunotherapy) for patients with anaplastic thyroid cancer (an aggressive, rare form of thyroid cancer) that does not have a BRAF mutation. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of anaplastic thyroid cancer (BRAF wild-type, meaning no BRAF V600E mutation) - Your overall physical health allows participation (ECOG performance status 0-2) - Your organ function (kidneys, liver, blood) meets required levels **You may NOT be eligible if...** - Your tumor tests positive for BRAF V600E mutation - You have active, untreated brain metastases - You have a history of severe autoimmune disease - You are pregnant or breastfeeding - You are currently on other investigational treatments Talk to your doctor to see if this trial is right for you.